Skip to main content
. 2021 Nov 1;24(12):103392. doi: 10.1016/j.isci.2021.103392

Figure 5.

Figure 5

Doxycycline reduces the number of MDSCs and synergistically enhances the anti-tumor activity of PD1 in 4T1 tumor-bearing model

(A, C, and E) Dot plots of the proportion of MDSCs (CD11b+Gr-1+) in bone marrows, spleens, and tumor cells from control and DOX-treated 4T1 tumor-bearing mice (n = 3).

(B, D, and F) Unpaired Student’s t test was done for statistical analyses of ratio of MDSCs in 4T1 tumor-bearing model. All data are represented as mean ± SEM. ∗∗p < 0.01, ∗∗∗p < 0.001.

(G) Tumor images of four groups to evaluate the anti-tumor effect of combination drug therapy of DOX and PD-1 in 4T1 tumor-bearing model.

(H) Tumor growth curves and statistical analysis of the four groups. The data are represented as mean ± SEM. ∗∗p < 0.01, ∗∗∗p < 0.001(Student t-test).

(I) Survival curve of the four groups. Survival analysis was performed by using the Kaplan-Meier method with log rank test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.